RNS Number : 8412J Stifel Nicolaus Europe Limited 09 April 2024 FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Name
LONDON and SALT LAKE CITY, April 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces a registered direct offering of ordinary shares at a purchase price equivalent to $0.75 per NASDAQ ADS ($0.375 per common stock share) (£0.0025 each) (the “ Ordinary Shares ”) (the “
RNS Number : 6587J Stifel Nicolaus Europe Limited 08 April 2024 FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Name
RNS Number : 6496J Renalytix PLC 08 April 2024 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES , CANADA , AUSTRALIA , JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A
RNS Number : 4934J Stifel Nicolaus Europe Limited 05 April 2024 FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Name
RNS Number : 5295J Renalytix PLC 05 April 2024 Renalytix plc ("Renalytix" or the "Company") Change of Registered Address LONDON and SALT LAKE CITY , April 5, 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on
RNS Number : 3100J Stifel Nicolaus Europe Limited 04 April 2024 FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Name
RNS Number : 2020J Renalytix PLC 03 April 2024 Renalytix plc ("Renalytix" or the "Company") Notice of General Meeting LONDON and SALT LAKE CITY , April 3, 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimising
RNS Number : 1337J Stifel Nicolaus Europe Limited 03 April 2024 FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Name
RNS Number : 9292I Stifel Nicolaus Europe Limited 02 April 2024 FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Name
